Department of Neurosurgery, School of Clinical Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Henan University, Zhengzhou, China.
Department of Orthopedics, School of Clinical Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Henan University, Zhengzhou, Henan, China.
J Mol Neurosci. 2022 Oct;72(10):2136-2149. doi: 10.1007/s12031-022-02054-2. Epub 2022 Aug 30.
An increasing number of evidences have shown that the carcinogenic effect of DRAXIN plays an important role in the malignant process of tumors, but the mechanism of its involvement in glioma has not yet been revealed. The main aim of this study is to explore the relationship between DRAXIN and the prognosis and pathogenesis of glioma through a large quality of data analysis. Firstly, thousands of tissue samples with clinical information were collected based on various public databases. Then, a series of bioinformatics analyses were performed to mine data from information of glioma samples extracted from several reputable databases to reveal the key role of DRAXIN in glioma development and progression, with the confirmation of basic experiments. Our results showed that high expression of the oncogene DRAXIN in tumor tissue and cells could be used as an independent risk factor for poor prognosis in glioma patients and was strongly associated with clinical risk features. The reverse transcription-quantitative PCR technique was then utilized to validate the DRAXIN expression results we obtained. In addition, co-expression analysis identified, respectively, top 10 genes that were closely associated with DRAXIN positively or negatively. Finally, in vitro experiments demonstrated that knockdown of DRAXIN significantly inhibited proliferation and invasion of glioma cell. To sum up, this is the first report of DRAXIN being highly expressed in gliomas and leading to poor prognosis of glioma patients. DRAXIN may not only benefit to explore the pathogenesis of gliomas, but also serve as a novel biological target for the treatment of glioma.
越来越多的证据表明，DRACIN 的致癌作用在肿瘤的恶性过程中起着重要作用，但它在神经胶质瘤中的作用机制尚未揭示。本研究的主要目的是通过大量质量数据分析探讨 DRACIN 与神经胶质瘤的预后和发病机制之间的关系。首先，基于各种公共数据库收集了数千个具有临床信息的组织样本。然后，通过对从几个著名数据库中提取的神经胶质瘤样本信息进行一系列生物信息学分析，挖掘数据，以揭示 DRACIN 在神经胶质瘤发生和发展中的关键作用，并通过基础实验进行验证。我们的研究结果表明，肿瘤组织和细胞中癌基因 DRACIN 的高表达可以作为神经胶质瘤患者预后不良的独立危险因素，与临床风险特征密切相关。然后，采用逆转录定量 PCR 技术验证我们获得的 DRACIN 表达结果。此外，通过共表达分析，分别确定了与 DRACIN 呈正相关或负相关的前 10 个密切相关的基因。最后，体外实验表明，DRACIN 敲低显著抑制了神经胶质瘤细胞的增殖和侵袭。总之，这是第一个报道 DRACIN 在神经胶质瘤中高表达并导致神经胶质瘤患者预后不良的报告。DRACIN 不仅有助于探讨神经胶质瘤的发病机制，而且可能成为治疗神经胶质瘤的新的生物学靶点。
